Kulandayan Subramanian

Kulandayan "Karthik" Subramanian has an extensive work experience in the field of pharmacology and pharmacometrics. In 2022, they became the Head of Clinical Pharmacology and Pharmacometrics at Werewolf Therapeutics. Prior to this, they were the Director of Quantitative Clinical Pharmacology at Daiichi Sankyo, Inc. from 2021. From 2009 to 2021, they worked at Novartis Institutes for BioMedical Research (NIBR) in various roles, including Senior Investigator / Associate Director, Senior Fellow, Associate Director Pharmacometrics, and Senior Modeler. Kulandayan "Karthik" was a Postdoctoral Research Fellow at Harvard Medical School / Children's Hospital from 2005 to 2009, where they characterized negative regulators of the PI3K/Akt pathway. From 2005 to 2006, they worked as a Research Associate at Encor Biotechnology. From 2000 to 2005, they were a Research Assistant at the University of Florida, where they focused on understanding the molecular mechanism underlying directed cell migration in response to extracellular stimuli.

Kulandayan "Karthik" Subramanian has a long and distinguished educational history. Kulandayan "Karthik" earned a Bachelor of Technology in Chemical Engineering from Sri Venkateshwara College of Engineering, University of Madras from 1995 to 1999. Kulandayan "Karthik" then went on to earn a PhD in Chemical Engineering from the University of Florida from 1999 to 2004.